Use of a three-microRNA signature to discriminate prognostic groups in early-stage NSCLC patients in the IFCT-0002 trial.
C. Mascaux
No relevant relationships to disclose
G. Levallet
No relevant relationships to disclose
E. Bergot
No relevant relationships to disclose
L. Baudrin
No relevant relationships to disclose
M. Antoine
No relevant relationships to disclose
G. Anthoine
No relevant relationships to disclose
V. Westeel
Honoraria - Lilly
A. Lavole
No relevant relationships to disclose
E. A. Quoix
Consultant or Advisory Role - Lilly
Honoraria - Lilly
D. Debieuvre
No relevant relationships to disclose
J. Mazieres
Honoraria - Lilly
J. Pujol
No relevant relationships to disclose
D. Moro-Sibilot
Consultant or Advisory Role - Lilly
Honoraria - Lilly
Other Remuneration - Lilly
F. Morin
Research Funding - Lilly
B. Milleron
Consultant or Advisory Role - Lilly
Honoraria - Lilly
Other Remuneration - Lilly
G. Zalcman
Consultant or Advisory Role - Bristol-Myers Squibb; Lilly
Honoraria - Lilly
Other Remuneration - Lilly